Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Parabilis MedicinesPBLS -4.66%10 Days Sales Outstanding is 0.00 as of Dec. 2025. GuruFocus rates PBLS with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 836 Biotechnology companies, Parabilis Medicines ranks worse than 119617.11% on this metric.
The historical rank and industry rank for Parabilis Medicines's Days Sales Outstanding or its related term are showing as below:
PBLS's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 68.89 * Ranked among companies with meaningful Days Sales Outstanding only.
Parabilis Medicines's Days Sales Outstanding
stayed the same
from . 20 (0.00) to Dec. 2025 (0.00).
Parabilis Medicines (NAS:PBLS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Parabilis Medicines Days Sales Outstanding Related Terms
Parabilis Medicines Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Parabilis Medicines's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parabilis Medicines Days Sales Outstanding Chart
Parabilis Medicines Annual Data
Trend
Dec24
Dec25
Days Sales Outstanding
0.00
0.00
Parabilis Medicines Semi-Annual Data
Dec24
Dec25
Days Sales Outstanding
0.00
0.00
PBLS vs IDYA, ELVN, BEAM: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Parabilis Medicines's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parabilis Medicines Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Parabilis Medicines's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Parabilis Medicines's Days Sales Outstanding falls into.
Parabilis Medicines Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parabilis Medicines (PBLS) has a Days Sales Outstanding of 0.00 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Parabilis Medicines and its competitors. According to the industry distribution chart, Parabilis Medicines ranks #999999 out of 836 companies in the Biotechnology industry.
Is Parabilis Medicines' Days Sales Outstanding too high?
Parabilis Medicines' current Days Sales Outstanding is 0.00. Based on the distribution chart, Parabilis Medicines ranks #999999 out of 836 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Parabilis Medicines has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Parabilis Medicines' Days Sales Outstanding compare to IDYA and ELVN?
According to the Biotechnology industry distribution chart, Parabilis Medicines ranks #999999 out of 836 companies for Days Sales Outstanding. This places Parabilis Medicines in the lower half of its industry. The industry median Days Sales Outstanding is 68.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.89, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Parabilis Medicines and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parabilis Medicines's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parabilis Medicines stock overvalued right now?
Parabilis Medicines (PBLS) has a current Days Sales Outstanding of 0.00. The current Days Sales Outstanding is 0.00. Parabilis Medicines' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Parabilis Medicines (PBLS), the current Days Sales Outstanding is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score
Get the complete analysis for PBLS
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBLS has been successfully added to your 
